IL1B and cancer: Moreover, considering that several of the active substances present in 2LMIREG, such as rh-IL-1β (10 CH), rh-IL-2 (10 CH), rh-TNF-α (10 CH), SNA®-HLA I (10 CH), SNA®-HLA II (10 CH), and finally, an rh-IL-2-targeting SNA® at 16 CH, are also present in another MIM, 2LARTH, which displayed anti-inflammatory effects both in vivo and in vitro [17,18,66], it would be of great interest to further study MIM-10 to assess its effect in counteracting the secretion of pro-inflammatory mediators induced by cancer cells.